retatrutide diabetes type 1 Retatrutide—A Game Changer in Obesity Pharmacotherapy Substack Series 3 of 6:

Starting at $349.99 /mo Mounjaro A once-weekly tirzepatide injection that activates two hormone receptors GIP and GLP-1 to reduce appetite, slow gastric emptying, and support metabolic health

| How these medications work | Head-to-head clinical evidence | Side effects and tolerability | Practical differences | Cost and access in the UK | Who might prefer each option

If you are eligible for a GLP-1, Noom Med has two different path options for you: Noom's GLP-1 Program and Noom's Microdose GLP-1 Program

Our dosage calculator guide helps determine the optimal vial size for your concentration needs

The cost to Medicare of covering obesity drugs under Part D has been estimated at between $25 billion and $35 billion over 10 years, which could have been a driving factor in the reluctance or unwillingness of major Part D plan sponsors to participate in the BALANCE model as it was originally designed